Charles Schwab Investment Management Inc. Acquires 298,778 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)

Charles Schwab Investment Management Inc. grew its holdings in Perspective Therapeutics, Inc. (NYSE:CATX) by 221.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 433,522 shares of the company’s stock after purchasing an additional 298,778 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.64% of Perspective Therapeutics worth $5,788,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the business. nVerses Capital LLC bought a new stake in Perspective Therapeutics during the third quarter worth about $57,000. US Bancorp DE boosted its stake in Perspective Therapeutics by 142.7% in the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after buying an additional 3,866 shares in the last quarter. Intech Investment Management LLC purchased a new position in shares of Perspective Therapeutics during the third quarter worth approximately $137,000. Los Angeles Capital Management LLC purchased a new position in shares of Perspective Therapeutics during the third quarter worth approximately $153,000. Finally, Victory Capital Management Inc. purchased a new stake in shares of Perspective Therapeutics in the 2nd quarter valued at $117,000. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on CATX. Cantor Fitzgerald restated an “overweight” rating on shares of Perspective Therapeutics in a report on Monday, September 9th. Truist Financial began coverage on shares of Perspective Therapeutics in a research report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price objective on the stock. Wedbush reiterated an “outperform” rating and set a $11.00 target price (down from $20.00) on shares of Perspective Therapeutics in a report on Thursday, November 21st. UBS Group started coverage on Perspective Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $20.00 price target for the company. Finally, Royal Bank of Canada cut their price objective on Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating on the stock in a research report on Monday, November 25th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Perspective Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.14.

Perspective Therapeutics Stock Up 0.6 %

CATX stock opened at $3.47 on Friday. The stock’s 50 day simple moving average is $8.99 and its 200 day simple moving average is $11.59. Perspective Therapeutics, Inc. has a 12-month low of $2.28 and a 12-month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.21). The business had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. As a group, equities research analysts anticipate that Perspective Therapeutics, Inc. will post -0.88 earnings per share for the current year.

Insider Activity

In other news, Director Heidi Henson acquired 25,975 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The shares were acquired at an average cost of $3.85 per share, with a total value of $100,003.75. Following the acquisition, the director now directly owns 25,975 shares of the company’s stock, valued at approximately $100,003.75. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Johan M. Spoor bought 14,500 shares of Perspective Therapeutics stock in a transaction dated Monday, November 25th. The stock was acquired at an average price of $3.78 per share, for a total transaction of $54,810.00. Following the completion of the acquisition, the chief executive officer now owns 152,072 shares in the company, valued at approximately $574,832.16. The trade was a 10.54 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 67,570 shares of company stock valued at $256,789 in the last ninety days. Corporate insiders own 3.52% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.